dr. chase on toxicities with niraparib in ovarian cancer
Published 4 years ago • 205 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
2:41
dr. chase on toxicities of treatments for ovarian cancer
-
1:38
dr. chase on niraparib as frontline maintenance therapy in ovarian cancer
-
0:57
dr. mirza on impact of niraparib in ovarian cancer
-
3:08
ovarian cancer: optimizing treatment with niraparib
-
6:31
prima: frontline niraparib maintenance therapy in ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
1:14
dr. chase discusses risk factors in gynecologic cancers
-
4:29
case 1: use of niraparib in ovarian cancer
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
6:35
parp inhibitor side effect management in ovarian cancer
-
40:03
ovarian cancer patient | sara's story: getting through surgery, chemo, parp inhibitor (video 2/3)
-
6:25
niraparib maintenance therapy for ovarian cancer
-
1:18
dr. pothuri on patient-reported outcomes with niraparib in advanced ovarian cancer
-
3:23
niraparib significantly improves outcomes for ovarian cancer patients
-
1:30
dr. mirza on niraparib efficacy across ovarian cancer subgroups
-
0:58
dr. matulonis on individualized dosing of niraparib in ovarian cancer
-
1:25
dr. konecny on the indications for parp inhibitors in recurrent ovarian cancer
-
6:57
niraparib maintenance for recurrent ovarian cancer
-
3:14
personalized dosing of niraparib in ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
1:14
dr. arend on niraparib with bevacizumab in ovarian cancer
-
2:03
dr. moore on treatment for patients with ovarian cancer who develop resistance to parp inhibitors